BullFrog AI announces USPTO issuance of patent for novel mebendazole prodrugs for cancer treatment

BullFrog AI Holdings, Inc.

USPTO to issue Patent No. 11,712,435 on Aug 1, 2023, protecting novel prodrugs of mebendazole with improved solubility and oral bioavailability.
This is the first patent from IP licensed from Johns Hopkins University in Oct 2022; BullFrog AI holds exclusive worldwide royalty-bearing rights.
CEO Vin Singh says prodrugs address key difficulty in evaluating mebendazole for oncology, enhancing potential for glioblastoma and other cancers.
Company intends to work with strategic partners to monetize the asset for clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.